U.S. markets open in 9 hours 26 minutes
  • S&P Futures

    4,441.75
    -33.00 (-0.74%)
     
  • Dow Futures

    34,498.00
    -118.00 (-0.34%)
     
  • Nasdaq Futures

    14,645.25
    -195.75 (-1.32%)
     
  • Russell 2000 Futures

    2,011.80
    -9.40 (-0.47%)
     
  • Crude Oil

    86.29
    -0.61 (-0.70%)
     
  • Gold

    1,842.20
    -0.40 (-0.02%)
     
  • Silver

    24.51
    -0.21 (-0.83%)
     
  • EUR/USD

    1.1328
    +0.0010 (+0.09%)
     
  • 10-Yr Bond

    1.8330
    +0.0060 (+0.33%)
     
  • Vix

    25.59
    +1.74 (+7.30%)
     
  • GBP/USD

    1.3594
    -0.0006 (-0.04%)
     
  • USD/JPY

    113.7880
    -0.3120 (-0.27%)
     
  • BTC-USD

    38,950.48
    -2,972.82 (-7.09%)
     
  • CMC Crypto 200

    920.12
    -75.14 (-7.55%)
     
  • FTSE 100

    7,585.01
    -4.65 (-0.06%)
     
  • Nikkei 225

    27,352.35
    -420.58 (-1.51%)
     

TRACON Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • TCON

SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 13-15, 2021.

The presentation will be available on-demand beginning at 7:00 AM Eastern Time on Monday, September 13, 2021, in the Investors section on the Company’s website at www.traconpharma.com.

About TRACON

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.

Company Contact:

Investor Contact:

Mark Wiggins

Brian Ritchie

Chief Business Officer

LifeSci Advisors LLC

(858) 251-3492

(212) 915-2578

mwiggins@traconpharma.com

britchie@lifesciadvisors.com